Inclusion Criteria:

- Confirmed malignancy

- Chemotherapy naive or treated with only low or minimally emetogenic chemotherapy
in the past (as defined by the National Comprehensive Cancer Network [NCCN] version
[v].2.201 Antiemetic Guidelines)

- Scheduled to receive the first dose of their first cycle of HEC

- Patients receiving multi-day chemotherapy, the HEC portion must be on day 1 and the
remaining days of chemotherapy must be minimally emetogenic (i.e. fluorouracil)

- Performance status of Eastern Cooperative Oncology Group (ECOG) grade 0-2

- Able to provide informed consent

- Able to read and write in English or have someone that can that can translate to them
and record their diary entries

- Able to take oral medications

- Patients are allowed to participate in a concurrent clinical trial, if the other
trial:

- Does not mandate an antiemetic regimen that interferes with this study

- Allows antiemetic administration at the physician's discretion

- Does not prohibit the patient from participating in this study

- Patients must be willing to participate with daily diary entries for 5 days following
chemotherapy, and agree to have a 5 minute follow-up call on day 2 or 3 and day 5, 6
or 7

Exclusion Criteria:

- Has stage IV (metastatic) disease

- Known hypersensitivity to ondansetron, palonosetron, aprepitant, or dexamethasone

- Have received or will receive agents that are strong cytochrome P450 3A4 (CYP450 3A4)
inducers and/or inhibitors and known to cause clinically relevant drug interactions
within one week prior to study treatment and continuing through day 5; any vomiting
or retching within 24 hours before administration of chemotherapy

- Grade 2 nausea or greater, according to the Common Terminology Criteria for Adverse
Events version 4.0 (CTCAE v 4.0) within 24 hours before administration of
chemotherapy

- Received an antiemetic within 24 hours before study drug administration, excluding
the use of benzodiazepines

- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2.5 times
upper limit of normal

- Total bilirubin > 1.5 times upper limit of normal